 |
|
The Effect of Isotretinoin in Six Patients With Cutaneous T-Cell Lymphoma
Sara M. Neely, MD;
Marilyn Mehlmauer, MD;
Donald I. Feinstein, MD
Arch Intern Med. 1987;147(3):529-531.
Abstract
• Oral retinoids are effective in the treatment of patients with a variety of malignant and nonmalignant skin disorders, including mycosis fungoides. We treated six patients with cutaneous T-cell lymphomas with isotretinoin 1 to 2 mg/kg/d. All patients experienced symptomatic relief (fading of skin lesions and disappearance of pruritus) within two to eight weeks of starting the drug therapy; pretreatment and posttreatment biopsy specimens were unchanged. Adverse effects were minor and primarily consisted of drying of the mucous membranes. We conclude that isotretinoin is a well-tolerated, easily administered drug that provides good palliation of symptoms and signs associated with cutaneous T-cell lymphoma in patients who are unable or unwilling to comply with standard therapy.
(Arch Intern Med 1987;147:529-531)
Author Affiliations
From the Department of Medicine, University of Southern California— Los Angeles County Medical Center.
Footnotes
Accepted for publication July 1, 1986.
Reprints not available.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results
Duvic et al.
JCO 2001;19:2456-2471.
ABSTRACT
| FULL TEXT
Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma
Duvic et al.
Arch Dermatol 2001;137:581-593.
ABSTRACT
| FULL TEXT
|
